📊 IMRX Key Takeaways
Is Immuneering Corp (IMRX) a Good Investment?
Immuneering is a pre-revenue clinical-stage biopharmaceutical company with zero commercial products and significant annual cash burn of $45.3M against $128.6M in cash reserves, providing approximately 2.8 years of runway. While the balance sheet is fortress-like with no debt and excellent liquidity, the complete lack of revenue generation combined with substantial operating losses (-$59.4M) represents unacceptable fundamental risk without clear near-term commercialization visibility.
Immuneering is a pre-revenue biotech with a very strong balance sheet—ample cash, no debt, and exceptional liquidity—providing an estimated multi-year runway at the current burn rate. Profitability remains negative but losses and EPS show YoY improvement, suggesting some operating discipline. With growth reliant on clinical progress rather than revenue scaling, fundamentals support a neutral stance pending tangible pipeline milestones.
Why Buy Immuneering Corp Stock? IMRX Key Strengths
- Fortress balance sheet with $128.6M cash and zero long-term debt (Debt/Equity: 0.00x)
- Exceptional liquidity position with 17.50x current ratio indicating no near-term solvency concerns
- Modest improvement in loss trajectory year-over-year (8.2% net income improvement, 37.7% EPS improvement)
- Low capital expenditure ($142.2K) suggesting focused pipeline rather than capital-intensive operations
- Robust cash & equivalents with no debt
- Exceptional liquidity (17.5x current ratio) and low liabilities
- Improving net loss and EPS YoY
IMRX Stock Risks: Immuneering Corp Investment Risks
- Zero revenue generation with no path to commercialization documented; company is pre-commercial stage
- Annual operating cash burn of $45.3M against $128.6M cash provides only 2.8-year runway before capital depletion
- Inherent biotech development risk: high probability of pipeline failures, regulatory rejections, or failed clinical trials
- Significant insider trading activity (13 Form 4 filings in 90 days) may signal insider concerns about development progress
- Negative operating margins and substantial operating losses (-$59.4M) unsustainable without revenue or funding
- Zero revenue with sustained operating losses
- High cash burn may require future dilution if timelines slip
- Clinical and regulatory execution risk typical of biotech
Key Metrics to Watch
- Quarterly operating cash burn rate trend and runway depletion timeline
- Clinical trial progress milestones and FDA regulatory feedback for lead candidates
- Capital raise activity and dilution impact; ability to fund operations through commercialization
- Revenue inflection from product approvals or licensing deals; transition from pure R&D burn
- Insider transaction patterns and magnitude; potential indicators of management confidence in pipeline
- Operating cash flow (quarterly)
- Cash & equivalents
Immuneering Corp (IMRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.50x current ratio provides a solid financial cushion.
IMRX Profit Margin, ROE & Profitability Analysis
IMRX vs Healthcare Sector: How Immuneering Corp Compares
How Immuneering Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immuneering Corp Stock Overvalued? IMRX Valuation Analysis 2026
Based on fundamental analysis, Immuneering Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immuneering Corp Balance Sheet: IMRX Debt, Cash & Liquidity
IMRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immuneering Corp's revenue has declined by 86% over the 5-year period, indicating business contraction. The most recent EPS of $-2.04 indicates the company is currently unprofitable.
IMRX Revenue Growth, EPS Growth & YoY Performance
IMRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$11.5M | $-0.43 |
| Q2 2023 | N/A | -$11.5M | $-0.43 |
| Q1 2023 | N/A | -$12.9M | $-0.49 |
| Q3 2022 | $38.4K | -$6.2M | $-0.47 |
| Q2 2022 | $94.4K | -$6.2M | $-0.44 |
| Q1 2022 | $183.7K | -$6.2M | $-0.49 |
| Q3 2021 | $482.1K | -$3.2M | $-0.47 |
| Q2 2021 | $480.8K | -$3.2M | $-0.73 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immuneering Corp Dividends, Buybacks & Capital Allocation
IMRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immuneering Corp (CIK: 0001790340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMRX
What is the AI rating for IMRX?
Immuneering Corp (IMRX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMRX's key strengths?
Claude: Fortress balance sheet with $128.6M cash and zero long-term debt (Debt/Equity: 0.00x). Exceptional liquidity position with 17.50x current ratio indicating no near-term solvency concerns. ChatGPT: Robust cash & equivalents with no debt. Exceptional liquidity (17.5x current ratio) and low liabilities.
What are the risks of investing in IMRX?
Claude: Zero revenue generation with no path to commercialization documented; company is pre-commercial stage. Annual operating cash burn of $45.3M against $128.6M cash provides only 2.8-year runway before capital depletion. ChatGPT: Zero revenue with sustained operating losses. High cash burn may require future dilution if timelines slip.
What is IMRX's revenue and growth?
Immuneering Corp reported revenue of $0.0.
Does IMRX pay dividends?
Immuneering Corp does not currently pay dividends.
Where can I find IMRX SEC filings?
Official SEC filings for Immuneering Corp (CIK: 0001790340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMRX's EPS?
Immuneering Corp has a diluted EPS of $-1.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Immuneering Corp has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMRX stock overvalued or undervalued?
Valuation metrics for IMRX: ROE of -25.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMRX stock in 2026?
Our dual AI analysis gives Immuneering Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMRX's free cash flow?
Immuneering Corp's operating cash flow is $-45.3M, with capital expenditures of $142.2K.
How does IMRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -25.6% (avg: 15%), current ratio 17.50 (avg: 2).